title: [Chronic hepatitis C with early complication of Grave's disease during the treatment of pegylated interferon alpha-2a].
authors.affiliation: Department of clinical research, National Hospital Organization Yokohama Medical Center, Yokohama.
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Maede
authors.forename: Keiichi
authors.initials: K
authors.lastname: Morishita
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Iwamura
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Takayama
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Tsukada
authors.forename: Maiko
authors.initials: M
authors.lastname: Kishino
authors.forename: Takeshi
authors.initials: T
authors.lastname: Shimizu
authors.forename: Shouzou
authors.initials: S
authors.lastname: Matsushima
authors.forename: Tatsuji
authors.initials: T
authors.lastname: Komatsu
authors.forename: Youko
authors.initials: Y
authors.lastname: Kasagi
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D042241:Early Diagnosis; D005260:Female; D006111:Graves Disease / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008713:Methimazole / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D008713:Methimazole; C100416:peginterferon alfa-2a